US7521219B2 - Method of producing baculovirus - Google Patents

Method of producing baculovirus Download PDF

Info

Publication number
US7521219B2
US7521219B2 US10/578,197 US57819704A US7521219B2 US 7521219 B2 US7521219 B2 US 7521219B2 US 57819704 A US57819704 A US 57819704A US 7521219 B2 US7521219 B2 US 7521219B2
Authority
US
United States
Prior art keywords
baculovirus
occlusion
mnpv
occlusion bodies
large quantities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/578,197
Other versions
US20070111295A1 (en
Inventor
Steven Reid
Linda Lua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003906171A external-priority patent/AU2003906171A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of US20070111295A1 publication Critical patent/US20070111295A1/en
Assigned to THE UNIVERSITY OF QUEENSLAND reassignment THE UNIVERSITY OF QUEENSLAND ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LUA, LINDA, REID, STEVEN
Application granted granted Critical
Publication of US7521219B2 publication Critical patent/US7521219B2/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14151—Methods of production or purification of viral material

Definitions

  • the present invention relates to the production of baculoviruses and in particular a method of producing commercial quantities of baculoviruses.
  • Baculoviruses have been used for a variety of applications including the production of recombinant proteins and use as biopesticides.
  • the problem with commercially using baculoviruses has been the inability to produce large amounts of infectious baculovirus.
  • FP mutants accumulate rapidly in cell culture due to spontaneous mutations in the 25K FP gene of the viral genome.
  • FP mutation is so rapid that by passage 6, the entire virus population is composed of FP mutants.
  • the yield is below 10 OB per cell and the OB produced are not biologically active (Lua, L. H. L., Pedrini, M., Reid, S., Robertson, A. & Tribe, D. E. (2002).
  • DIPs Phenotypic and genotypic analysis of Helicoverpa armigera nucleopolyhedrovirus serially passaged in cell culture. Journal of General Virology 83, 947-957). Similarly DIPs can also accumulate rapidly during serial passaging of Baculoviruses with high MOls in cell culture. DIPs of AcMNPV infection have been detected as early as passage 4 when an MOI of 10 PFU per cell was used. DIPs are the result of large deletions in the virus genome. DIPs require a ‘helper virus’ (wild-type virus) for replication (Pijilman, G. P., van den Born, E., Martens, D. E. & Vlak, J. M. (2001). Autographa californica baculoviruses with large genomic deletions are rapidly generated in infected insect cells. Virology 283, 132-138). The occurrence of these mutations cause problems during the scale-up from virus inoculum to large scale production.
  • FP mutation during serial passaging of HaSNPV poses a greater threat to scale-up of a production process than does the appearance of DIPs. FP mutations occur much faster and earlier than DIPs, regardless of the MOI.
  • infectious OB In cell culture, there does not appear to be any selection pressure for infectious OB.
  • FP mutant infected cells bud more baculovirus than MP (many polyhedra) infected cells thereby providing a selective advantage for FP mutants.
  • infectious OB In larvae and unlike in cell. culture, infectious OB have a selective advantage in being the form of baculovirus transmitted to other larvae (Potter, K. N., Jaques, R. P. & Faulkner, P. (1978). Modification of Trichoplusia ni nuclear polyhedrosis virus passaged in vivo. Intervirology 9, 76-85).
  • Serial passaging may produce large amounts of baculovirus but the virus is not infectious.
  • Production of large quantities of virus from caterpillar larvae is impractical because of the large numbers of larvae required and difficulties in subsequent large scale purification necessary to isolate the virus.
  • Methods of extracting occlusion derived virus from occlusion bodies after each passage during large volume production is also very difficult technically and impractical. It would be necessary for the occlusion bodies to be extracted from the cells and concentrated after each passage while maintaining sterility during the whole process.
  • the present invention was conceived and reduced to practice by the need to produce commercial quantities of infective baculovirus OB.
  • the present invention was conceived by identifying the advantage of producing occlusion bodies with infectious baculovirus in caterpillar larvae and large numbers of viral particles with serial passages in cell culture.
  • a two step method was then developed by initially producing infectious virus in caterpillar larvae and then using the resultant infectious virus as an inoculum for a limited number of serial passages in cell culture so to produce large amounts of infectious baculovirus.
  • the present invention resides in a method of producing large quantities of baculovirus including inoculating caterpillar larvae with a baculovirus inoculum;
  • the incubation of the virus/cell culture is preferably for a period of time that enables four or five passages of baculovirus.
  • Baculovirus is used in the specification as a general term encompassing different baculovirus species including Helicoverpa armigera SNPV, Helicoverpa zea SNPV, Spodoptera frugiperda MNPV, Anticarsia gemmatalis MNPV, Autographa californica MNPV, Anagrapha falcifera MNPV, Lymantria dispar MNPV, Bombyx mori MNPV, Spodoptera exigua MNPV, Trichoplusia ni MNPV, Orgyia pseudotsugata MNPV and Buzura suppressaria SNPV.
  • a preferred baculovirus is a Helicoverpa armigera isolate.
  • a preferred Helicoverpa armigera isolate is strain H25EA1.
  • the original baculovirus inoculum may be derived from any suitable source including occlusion bodies from larvae or cell culture.
  • baculovirus may be produced from larvae in an initial step to form an occlusion bodies master stock.
  • the occlusion bodies master stock may then be used to provide inoculum for the production of occlusion bodies working stocks.
  • an occlusion bodies working stock preferably has approximately 2 ⁇ 10 12 occlusion bodies whereas occlusion bodies master stock has approximately 10 9 occlusion bodies. Both the master stock and working stock may be stored at 4 degrees Celsius or frozen.
  • the occlusion derived virus is inoculated in the cell culture at a relatively high MOI.
  • an inoculum of occlusion derived virus is obtained from as low as 2.5 ⁇ 10 10 occlusion bodies and introduced into a ten litre bioreactor containing 5 ⁇ 10 5 cells per ml.
  • the culture is progressively scaled up from a 10 litre volume (P1) to a 100 litre volume (P2), then to a 1,000 litre volume (P3) and finally a 10,000 litre volume (P4).
  • the 10 litre culture produces approximately 10 7 PFU (Baculovirus) per ml.
  • the 10,000 litre culture preferably has an approximate cell density between 1.5-2.0 ⁇ 10 9 cells per litre and a 2.5 ⁇ 10 11 OB per litre (which is approximately 150 OB per cell).
  • the OB have a LC50 against heliothis caterpillars of 0.2-1.0 OB per mm 2 .
  • the extraction of the occlusion derived virus from the working stock may occur by any suitable method.
  • Occlusion derived virus is preferably extracted using alkali to lyse the occlusion bodies and the resultant viral particles are stabilized in an appropriate buffering media.
  • the preferred method of extraction includes mixing an alkaline solution with an OB suspension and incubating the mixture for a period of time and at a temperature that separates the viral particles.
  • the ODV are then preferably suspended in a stabilizing media preferably VPM3 (disclosed in FIG. 2 ).
  • Preferably no acid neutralization step is included.
  • the preferred ODV extraction method is the VPM3 extraction method outlined below.
  • the VPM3 extraction method has the advantages that it does not use a trypsin treatment and VPM3 media does not contain serum thus making the method more economical than the conventional methods and therefore more suitable for large scale commercial production.
  • the invention broadly resides in the Baculovirus product produced from the above mentioned method.
  • the Baculovirus product is characterized by being the amount of infectious baculovirus of approximately 2.5 ⁇ 10 15 OB with a LC50 against Helicoverpa spp caterpillars of 0.2-1.0 OB per mm 2 .
  • This quantity of infectious Baculovirus has not previously been obtainable from a single in vitro method of production.
  • a further advantage is that this quantity of infectious Baculovirus is economically producible.
  • the resultant Baculovirus can be used for a variety of purposes including as a biopesticide.
  • Helicoverpa armigera OB can be applied to crops at 5 ⁇ 10 11 to 5 ⁇ 10 12 OB per Ha to ensure control of the H. armigera caterpillar pest.
  • FIG. 1 is a diagrammatic representation of the method of producing large amounts of Baculovirus
  • FIG. 2 shows the formulation of the extraction stabilization media VPM3 of the preferred embodiment
  • FIG. 3 compares the number OB used for extraction and resultant OB per cell at passage 4;
  • FIG. 4 shows the OB yield over 4 passages using two samples (flasks A and B).
  • the preferred embodiment of the method for producing large quantities of baculovirus involves a two step process of initially producing virus in caterpillar larvae and then using occlusion derived virus from a caterpillar larvae to inoculate a cell culture and allow a limited number of serial passages of the cell culture (see FIG. 1 ).
  • the method initially involves preparing master and working stocks of caterpillar larvae occlusion bodies.
  • the master and working stocks of caterpillar OB are prepared by feeding large Helicoverpa armigera larvae approximately 1,000 OB each. As they die (6-10 days post infection) they are collected and stored at 4° C. Approximately 1.5-2 larvae are required for a 10 litre (passage 1) inoculum as 2.5 ⁇ 10 10 OB are required per run and approximately 1.7 ⁇ 10 10 OB are produced per larvae.
  • After a sufficient number of dead caterpillars are pooled, they are extracted with SDS (30 minutes, 0.5% final concentration), homogenized (blender process), filtered (cheesecloth), spun down and suspended in water (10 10 OB/ml). A number of water washes can be carried out to help remove excess debris.
  • the OB suspension can be stored refrigerated or frozen.
  • the OB are extracted using the VPM3 extraction method which includes the steps of adding 40 ⁇ l of alkaline solution (0.5 M Na 2 CO 3 , 1 M NaCl) for each 0.7 ml OB suspension (10 10 OB/ml), the mixture is well mixed and incubated at 28° C. for 30 minutes. The incubated OB mixture is then diluted with 10 ml of VPM3 media for each 0.74 ml of extracted OB (see FIG. 2 for formulation of VPM3). The diluted ODV suspension is then filter sterilized through a 0.22 ⁇ m filter. The resultant ODV suspension is then used as inoculum.
  • VPM3 extraction method includes the steps of adding 40 ⁇ l of alkaline solution (0.5 M Na 2 CO 3 , 1 M NaCl) for each 0.7 ml OB suspension (10 10 OB/ml), the mixture is well mixed and incubated at 28° C. for 30 minutes. The incubated OB mixture is then diluted with 10 ml of VPM3 media for each
  • FIG. 3 shows examples of yields of OB per cell used for extraction and resultant yield of OB per cell at passage 4.
  • the baculovirus inoculated 10 litre culture was aerobically incubated in a bioreactor at 28° C. for approximately 3 days.
  • the incubation is passage 1.
  • the fermentation was gradually scaled up so that passages 2, 3 and 4 were 100 litres, 1,000 litres and 10,000 litres respectively. All the incubations were aerated at 28° C. for approximately 2 days, except the final incubation which was for 10-15 days.
  • the 10,000 litre culture has an approximate cell density between 1.5-2.0 ⁇ 10 9 cells per litre and 2.5 ⁇ 10 11 OB per litre (which is approximately 150 OB per cell).
  • the OB had a LC50 against Helicoverpa spp caterpillars of 0.2-1.0 OB per mm 2 .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention is directed to a method for producing commercial quantities of baculovirus using a combination of methods involving producing occlusion bodies with infectious baculovirus in caterpillar larvae and large numbers of viral particles with serial passages in cell culture. A two step method was developed by initially producing infectious virus in caterpillar larvae and then using the resultant infectious virus as an inoculum for a limited number of serial passages in cell culture so to produce large amounts of infectious baculovirus.

Description

FIELD OF INVENTION
The present invention relates to the production of baculoviruses and in particular a method of producing commercial quantities of baculoviruses.
PRIOR ART
Baculoviruses have been used for a variety of applications including the production of recombinant proteins and use as biopesticides. The problem with commercially using baculoviruses has been the inability to produce large amounts of infectious baculovirus.
Economic commercial production of baculoviruses requires production of at least 10,000 litre culture with a virus yield greater than 150 OB (occlusion bodies) per cell (Greenfield, P. F., Reid, S., Weiss, S. & Scholz, B. (1999). Baculoviruses as biological control agents: research, production and commercial issues. In The 5th Asia-Pacific Biochemical Engineering Conference Proceedings. Phuket, Thailand). The standard scale-up process for large scale baculovirus production requires up to 5 passages of baculovirus in cell culture to obtain enough virus for a frozen Baculovirus working stock. A further 6 passages are required to scale-up the production process to 10,000 litre scale in order to achieve economical production (Rhodes, D. J. (1996). Economics of baculovirus-insect cell production systems. Cytotechnology 20, 291-297). According to this standard scale-up process, it will take 11 passages to obtain the final virus product at 10,000 litre scale, assuming that the virus is stable during serial passaging and is still producing more than 150 OB per cell.
Baculoviruses however are not stable during serial passaging in cell culture as they appear to mutate spontaneously to form FP (few polyhedra) mutants or DIP (defective interfering particles) mutants. FP mutants accumulate rapidly in cell culture due to spontaneous mutations in the 25K FP gene of the viral genome. For HaSNPV, FP mutation is so rapid that by passage 6, the entire virus population is composed of FP mutants. The yield is below 10 OB per cell and the OB produced are not biologically active (Lua, L. H. L., Pedrini, M., Reid, S., Robertson, A. & Tribe, D. E. (2002). Phenotypic and genotypic analysis of Helicoverpa armigera nucleopolyhedrovirus serially passaged in cell culture. Journal of General Virology 83, 947-957). Similarly DIPs can also accumulate rapidly during serial passaging of Baculoviruses with high MOls in cell culture. DIPs of AcMNPV infection have been detected as early as passage 4 when an MOI of 10 PFU per cell was used. DIPs are the result of large deletions in the virus genome. DIPs require a ‘helper virus’ (wild-type virus) for replication (Pijilman, G. P., van den Born, E., Martens, D. E. & Vlak, J. M. (2001). Autographa californica baculoviruses with large genomic deletions are rapidly generated in infected insect cells. Virology 283, 132-138). The occurrence of these mutations cause problems during the scale-up from virus inoculum to large scale production.
FP mutation during serial passaging of HaSNPV poses a greater threat to scale-up of a production process than does the appearance of DIPs. FP mutations occur much faster and earlier than DIPs, regardless of the MOI.
In cell culture, there does not appear to be any selection pressure for infectious OB. FP mutant infected cells bud more baculovirus than MP (many polyhedra) infected cells thereby providing a selective advantage for FP mutants. In larvae and unlike in cell. culture, infectious OB have a selective advantage in being the form of baculovirus transmitted to other larvae (Potter, K. N., Jaques, R. P. & Faulkner, P. (1978). Modification of Trichoplusia ni nuclear polyhedrosis virus passaged in vivo. Intervirology 9, 76-85).
Serial passaging may produce large amounts of baculovirus but the virus is not infectious. Production of large quantities of virus from caterpillar larvae is impractical because of the large numbers of larvae required and difficulties in subsequent large scale purification necessary to isolate the virus. Methods of extracting occlusion derived virus from occlusion bodies after each passage during large volume production is also very difficult technically and impractical. It would be necessary for the occlusion bodies to be extracted from the cells and concentrated after each passage while maintaining sterility during the whole process.
At present, there are no methods of economically producing large commercial quantities of infectious baculovirus.
OBJECT OF THE INVENTION
It is an object of the present invention to provide an alternative method of producing large quantities of baculovirus.
SUMMARY OF THE INVENTION
The present invention was conceived and reduced to practice by the need to produce commercial quantities of infective baculovirus OB. The present invention was conceived by identifying the advantage of producing occlusion bodies with infectious baculovirus in caterpillar larvae and large numbers of viral particles with serial passages in cell culture. A two step method was then developed by initially producing infectious virus in caterpillar larvae and then using the resultant infectious virus as an inoculum for a limited number of serial passages in cell culture so to produce large amounts of infectious baculovirus.
In one aspect the present invention resides in a method of producing large quantities of baculovirus including inoculating caterpillar larvae with a baculovirus inoculum;
incubating inoculated caterpillar larvae;
harvesting baculovirus occlusion bodies from the infected caterpillar larvae;
extracting occlusion derived virus from the occlusion bodies;
inoculating a culture of host insect cells with an inoculum of occlusion derived virus;
incubating virus/cell culture; and
harvesting baculovirus from the incubated virus/cell culture.
The incubation of the virus/cell culture is preferably for a period of time that enables four or five passages of baculovirus.
Baculovirus is used in the specification as a general term encompassing different baculovirus species including Helicoverpa armigera SNPV, Helicoverpa zea SNPV, Spodoptera frugiperda MNPV, Anticarsia gemmatalis MNPV, Autographa californica MNPV, Anagrapha falcifera MNPV, Lymantria dispar MNPV, Bombyx mori MNPV, Spodoptera exigua MNPV, Trichoplusia ni MNPV, Orgyia pseudotsugata MNPV and Buzura suppressaria SNPV. A preferred baculovirus is a Helicoverpa armigera isolate. A preferred Helicoverpa armigera isolate is strain H25EA1.
The original baculovirus inoculum may be derived from any suitable source including occlusion bodies from larvae or cell culture.
There may be more than one step of producing baculovirus from larvae in order to produce a suitable amount of occlusion bodies working stock. In one preferred form, baculovirus may be produced from larvae in an initial step to form an occlusion bodies master stock. The occlusion bodies master stock may then be used to provide inoculum for the production of occlusion bodies working stocks. In a preferred form, an occlusion bodies working stock preferably has approximately 2×1012 occlusion bodies whereas occlusion bodies master stock has approximately 109 occlusion bodies. Both the master stock and working stock may be stored at 4 degrees Celsius or frozen.
Preferably the occlusion derived virus (ODV) is inoculated in the cell culture at a relatively high MOI. In a preferred embodiment, an inoculum of occlusion derived virus is obtained from as low as 2.5×1010 occlusion bodies and introduced into a ten litre bioreactor containing 5×105 cells per ml. The culture is progressively scaled up from a 10 litre volume (P1) to a 100 litre volume (P2), then to a 1,000 litre volume (P3) and finally a 10,000 litre volume (P4). The 10 litre culture produces approximately 107 PFU (Baculovirus) per ml. The 10,000 litre culture preferably has an approximate cell density between 1.5-2.0×109 cells per litre and a 2.5×1011 OB per litre (which is approximately 150 OB per cell). The OB have a LC50 against heliothis caterpillars of 0.2-1.0 OB per mm2.
The extraction of the occlusion derived virus from the working stock may occur by any suitable method. Occlusion derived virus is preferably extracted using alkali to lyse the occlusion bodies and the resultant viral particles are stabilized in an appropriate buffering media. The preferred method of extraction includes mixing an alkaline solution with an OB suspension and incubating the mixture for a period of time and at a temperature that separates the viral particles. The ODV are then preferably suspended in a stabilizing media preferably VPM3 (disclosed in FIG. 2). Preferably no acid neutralization step is included. The preferred ODV extraction method is the VPM3 extraction method outlined below. The VPM3 extraction method has the advantages that it does not use a trypsin treatment and VPM3 media does not contain serum thus making the method more economical than the conventional methods and therefore more suitable for large scale commercial production.
In another aspect the invention broadly resides in the Baculovirus product produced from the above mentioned method. The Baculovirus product is characterized by being the amount of infectious baculovirus of approximately 2.5×1015 OB with a LC50 against Helicoverpa spp caterpillars of 0.2-1.0 OB per mm2. This quantity of infectious Baculovirus has not previously been obtainable from a single in vitro method of production. A further advantage is that this quantity of infectious Baculovirus is economically producible.
The resultant Baculovirus can be used for a variety of purposes including as a biopesticide. By way of example Helicoverpa armigera OB can be applied to crops at 5×1011 to 5×1012 OB per Ha to ensure control of the H. armigera caterpillar pest.
BRIEF DESCRIPTION OF THE DRAWINGS
In order that the present invention be more readily understood and put into practical effect, reference will now be made to the accompanying drawings wherein:
FIG. 1 is a diagrammatic representation of the method of producing large amounts of Baculovirus;
FIG. 2 shows the formulation of the extraction stabilization media VPM3 of the preferred embodiment;
FIG. 3 compares the number OB used for extraction and resultant OB per cell at passage 4; and
FIG. 4 shows the OB yield over 4 passages using two samples (flasks A and B).
 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The preferred embodiment of the method for producing large quantities of baculovirus involves a two step process of initially producing virus in caterpillar larvae and then using occlusion derived virus from a caterpillar larvae to inoculate a cell culture and allow a limited number of serial passages of the cell culture (see FIG. 1).
The method initially involves preparing master and working stocks of caterpillar larvae occlusion bodies. The master and working stocks of caterpillar OB are prepared by feeding large Helicoverpa armigera larvae approximately 1,000 OB each. As they die (6-10 days post infection) they are collected and stored at 4° C. Approximately 1.5-2 larvae are required for a 10 litre (passage 1) inoculum as 2.5×1010 OB are required per run and approximately 1.7×1010 OB are produced per larvae. After a sufficient number of dead caterpillars are pooled, they are extracted with SDS (30 minutes, 0.5% final concentration), homogenized (blender process), filtered (cheesecloth), spun down and suspended in water (1010 OB/ml). A number of water washes can be carried out to help remove excess debris. The OB suspension can be stored refrigerated or frozen.
The OB are extracted using the VPM3 extraction method which includes the steps of adding 40 μl of alkaline solution (0.5 M Na2CO3, 1 M NaCl) for each 0.7 ml OB suspension (1010 OB/ml), the mixture is well mixed and incubated at 28° C. for 30 minutes. The incubated OB mixture is then diluted with 10 ml of VPM3 media for each 0.74 ml of extracted OB (see FIG. 2 for formulation of VPM3). The diluted ODV suspension is then filter sterilized through a 0.22 μm filter. The resultant ODV suspension is then used as inoculum.
FIG. 3 shows examples of yields of OB per cell used for extraction and resultant yield of OB per cell at passage 4.
Approximately 2.5×1010 OB are required to produce enough ODV for use as an inoculum to infect a 10 litre culture (5×105 cells/ml).
The baculovirus inoculated 10 litre culture was aerobically incubated in a bioreactor at 28° C. for approximately 3 days. The incubation is passage 1. The fermentation was gradually scaled up so that passages 2, 3 and 4 were 100 litres, 1,000 litres and 10,000 litres respectively. All the incubations were aerated at 28° C. for approximately 2 days, except the final incubation which was for 10-15 days.
The 10,000 litre culture has an approximate cell density between 1.5-2.0×109 cells per litre and 2.5×1011 OB per litre (which is approximately 150 OB per cell). The OB had a LC50 against Helicoverpa spp caterpillars of 0.2-1.0 OB per mm2.
In a further example shown in FIG. 4, 1011 OB were successfully extracted and filtered. The filtered sterilized extraction was sampled to infect duplicate 100 ml cultures (flasks A and B). The OB yields after passage 4 (10,000 litre culture) were relatively high with 263 and 239 OB per cell obtained from flasks A and B respectively.
Variations
It will of course be realised that while the foregoing has been given by way of illustrative example of this invention, all such and other modifications and variations thereto as would be apparent to persons skilled in the art are deemed to fall within the broad scope and ambit of this invention as is herein set forth.
Throughout the description and claims this specification the word “comprise” and variations of that word such as “comprises” and “comprising”, are not intended to exclude other additives, components, integers or steps.

Claims (10)

1. A method of producing large quantities of baculovirus including
inoculating caterpillar larvae with a baculovirus inoculum;
incubating inoculated caterpillar larvae;
harvesting baculovirus occlusion bodies (OBs) from the infected caterpillar larvae;
extracting occlusion derived virus from the occlusion bodies;
inoculating a culture of host insect cells with an inoculum of occlusion derived virus;
incubating virus/cell culture; and
harvesting baculovirus from the incubated virus/cell culture, wherein the incubation of the virus/cell culture is for a period of time that enables four or five passages of baculovirus.
2. A method of producing large quantities of baculovirus as claimed in claim 1, wherein the baculovirus is selected from any one of the following group: Helicoverpa armigera SNPV, Helicoverpa zea SNPV, Spodoptera frugiperda MNPV, Anticarsia gemmatalis MNPV, Autographa californica MNPV, Anagrapha falcifera MNPV, Lymantria dispar MNPV, Bombyx mori MNPV, Spodoptera exigua MNPV, Trichoplusia ni MNPV, Orgyia pseudotsugata MNPV and Buzura suppressaria SNPV.
3. A method of producing large quantities of baculovirus as claimed in claim 1, wherein the baculovirus is a Helicoverpa armigera isolate.
4. A method of producing large quantities of baculovirus as claimed in claim 1, wherein there is more than one step of producing baculovirus from larvae in order to produce a suitable amount of occlusion bodies working stock, and the suitable amount of occlusion bodies working stock has approximately 2×1012 occlusion bodies.
5. A method of producing large quantities of baculovirus as claimed in claim 1, wherein the occlusion derived virus (ODV) is inoculated in the cell culture at an MOI that can be as low as 2.5×1010 occlusion bodies to 5×10 5 cells per ml.
6. A method of producing large quantities of baculovirus as claimed in claim 1, wherein an inoculum of occlusion derived virus is obtained from as low as 2.5×1010 occlusion bodies and introduced into a ten liter bioreactor containing 5×105 cells per ml, the culture is then progressively scaled up from a 10 liter volume (P1) to a 100 liter volume (P2), then to a 1,000 liter volume (P3) and finally a 10,000 liter volume (P4); wherein the 10 liter culture producea approximately 107 PFU (Baculovirus) per ml,the 10,000 liter cultuer has an approximate cell density between 1.5-2.0 ×109 cells per liter and a 2.5×1011 OB per liter (which is approximately 150 OB per cell) and the OB has a LC50 against heliothis caterpillars of between 0.2-1 0 OB per mm2.
7. A method of producing large quantities of baculovirus as claimed in claim 1, wherein the occlusion derived virus is extracted using alkali to lyse the occlusion bodies and the resultant viral particles are stabilized in an appropriate buffering media.
8. A method of producing large quantities of baculovirus as claimed in claim 1, wherein the method of extraction includes mixing an alkaline solution with an OB suspension and incubating the mixture for a period of time and at a temperature that separates the viral particles, the ODV are then suspended in VPM3 stabilizing media; the ODV is extracted without the use of a trypsin treatment and without the use of serum.
9. A method of producing large quantities of baculovirus as claimed in claim 4, wherein the baculovirus are produced from larvae in an initial step to form an occlusion bodies master stock, the occlusion bodies master stock is then used to provide inoculum for the production of occlusion bodies working stocks.
10. A method of producing large quantities of baculovirus as claimed in claim 9, wherein an inculum of extracted occlusion derived virus has approximately 2×1012 occlusion bodies whereas the baculovirus inoculum for the initial step has approximately 109 occlusion bodies.
US10/578,197 2003-11-10 2004-11-10 Method of producing baculovirus Expired - Fee Related US7521219B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003906171 2003-11-10
AU2003906171A AU2003906171A0 (en) 2003-11-10 Method of Producing Baculovirus
PCT/AU2004/001549 WO2005045014A1 (en) 2003-11-10 2004-11-10 Method of producing baculovirus

Publications (2)

Publication Number Publication Date
US20070111295A1 US20070111295A1 (en) 2007-05-17
US7521219B2 true US7521219B2 (en) 2009-04-21

Family

ID=34558189

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/578,197 Expired - Fee Related US7521219B2 (en) 2003-11-10 2004-11-10 Method of producing baculovirus

Country Status (12)

Country Link
US (1) US7521219B2 (en)
EP (1) EP1692280A4 (en)
JP (1) JP5072362B2 (en)
KR (1) KR20070012315A (en)
CN (1) CN1902308B (en)
BR (1) BRPI0416345A (en)
CA (1) CA2545177A1 (en)
EA (1) EA012067B1 (en)
IL (1) IL175519A0 (en)
MX (1) MXPA06005178A (en)
WO (1) WO2005045014A1 (en)
ZA (1) ZA200603541B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2662960C1 (en) * 2017-12-08 2018-07-31 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Lymantria dispar l. gipsy moth nuclear polyhedrosis virus strain used for the production of insecticide drugs
CN114190333A (en) * 2021-10-26 2022-03-18 中国农业科学院烟草研究所(中国烟草总公司青州烟草研究所) A kind of propagation method of dicistronic virus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042843A (en) * 1996-11-25 2000-03-28 The United States Of America As Represented By The Secretary Of Agriculture Baculovirus for the control of insect pests

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Bull, J.C. et al., (Apr. 2003), A few-polyhedra mutant and wild-type nucleopolyhedrovirus remain as a stable polymorphism during serial coinfection in Trichoplusia ni, Applied and Environmental Microbiology, 69: 2052-2057.
Chakraborty, S. and Reid, S., 1999, Serial passage of a Helicoverpa armigera nucleopolyhedrovirus in Helicoverpa zea cell cultures, Journal of Invertebrate Pathology, 73: 303-308.
Chakraborty, S. et al., 1995, In vitro production of wild type Heliothis baculoviruses for use as biopesticides, Australasian Biotechnology, 5: 82-86.
Lua, L.H.L. et al., 2002, Phenotypic and genotypic analysis of Helicoverpa armigera nucleopolyhedrovirus serially passaged in cell culture, Journal of General Virology, 83: 945-955.
Slavicek, J.M. et al., 1996, Isolation of a baculovirus variant that exhibits enhanced polyhedra production stability during serial passage in cell culture, Journal of Invertebrate Pathology, 67: 153-160.
Volkman et al., J. Virol., 1976, vol. 19, No. 3, pp. 820-832. *
Wong, K.T.K. et al., 1996, Low multiplicity infection of insect cells with a recombinant baculovirus: the cell yield concept, Biotechnology and Bioengineering, 49: 659-666.

Also Published As

Publication number Publication date
EP1692280A1 (en) 2006-08-23
EP1692280A4 (en) 2007-11-28
CA2545177A1 (en) 2005-05-19
WO2005045014A1 (en) 2005-05-19
CN1902308B (en) 2012-09-26
BRPI0416345A (en) 2007-01-16
CN1902308A (en) 2007-01-24
MXPA06005178A (en) 2007-02-16
IL175519A0 (en) 2006-09-05
EA200600937A1 (en) 2007-02-27
EA012067B1 (en) 2009-08-28
ZA200603541B (en) 2007-08-29
JP2007510418A (en) 2007-04-26
JP5072362B2 (en) 2012-11-14
KR20070012315A (en) 2007-01-25
US20070111295A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
US20230059552A1 (en) Virus-free cell lines and methods for obtaining same
Jarvis Baculovirus–insect cell expression systems
WO1996006161A1 (en) Establishment of trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production
Taticek et al. Comparison of growth and recombinant protein expression in two different insect cell lines in attached and suspension culture
Slavicek et al. Isolation of a baculovirus variant that exhibits enhanced polyhedra production stability during serial passage in cell culture
Wang et al. Studies on serum-free culture of insect cells for virus propagation and recombinant protein production
Goodman et al. Production of baculoviruses for insect control using cell culture
van Lier et al. Long-term semi-continuous production of recombinant baculovirus protein in a repeated (fed-) batch two-stage reactor system
US7521219B2 (en) Method of producing baculovirus
Chakraborty et al. Serial Passage of aHelicoverpa armigeraNucleopolyhedrovirus inHelicoverpa zeaCell Cultures
Eason et al. Effects of substituting granulin or a granulin-polyhedrin chimera for polyhedrin on virion occlusion and polyhedral morphology in Autographa californica multinucleocapsid nuclear polyhedrosis virus
AU2004287903B2 (en) Method of producing baculovirus
Goodman et al. Production of selected baculoviruses in newly established lepidopteran cell lines
Wu et al. New cell lines from Lymantria xylina (Lepidoptera: Lymantriidae): characterization and susceptibility to baculoviruses
Harrison et al. New cell lines derived from the black cutworm, Agrotis ipsilon, that support replication of the A. ipsilon multiple nucleopolyhedrovirus and several group I nucleopolyhedroviruses
Kamiya et al. Genotypic variation of a wild isolate of Hyphantria cunea nucleopolyhedrovirus
Castro et al. Infectivity of Anticarsia gemmatalis nucleopolyhedrovirus to different insect cell lines: Morphology, viral production, and protein synthesis
US6379958B1 (en) Selected insect cell line clones providing increased yield of baculoviruses and gene expression products from recombinant baculoviruses
US5405770A (en) Heliothis subflexa cell line for the production of baculoviruses
Taticek Enhanced recombinant protein expression in baculovirus-infected high-density insect cell suspension cultures and the operations of a continuous flow bioreactor
EP0638124B1 (en) Oral infection of insect larvae with pre-occluded baculovirus particles
Lynn Comparison of cell line maintenance procedures on insect cells used for producing baculoviruses
Mannix et al. A guide to successful scale-up of the baculovirus expression system
McIntosh et al. In vitro host range of the Hz-1 nonoccluded virus in insect cell lines
WO1995023215A1 (en) A process for producing viruses, viral proteins and recombinant proteins

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: THE UNIVERSITY OF QUEENSLAND, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REID, STEVEN;LUA, LINDA;REEL/FRAME:022518/0921

Effective date: 20041110

Owner name: THE UNIVERSITY OF QUEENSLAND,AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REID, STEVEN;LUA, LINDA;REEL/FRAME:022518/0921

Effective date: 20041110

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20130421